LEGN Healthcare

Legend Biotech Corporation

$21.48+1.80%

Price as of close on Nov 3, 2026 · Financials updated Sep 30, 2026

Basics

Sector: Healthcare
Industry: Biotechnology
Country: United States
Market cap: 4.2B USD
Enterprise value: 3.0B USD
Full-time employees: 3,200

Overall health

Strength: growing faster than most peersgrowing faster than peers
Drawback: less profitable than most peersless profitable than peers
Drawback: its shares are priced higher than most peers relative to what it earnspriced higher than peers for its earnings
About average: risk (debt, liquidity and share-price swings)risk

Ranks #753 of 1,157 healthcare companies (bottom 36%)

See how it ranks against its peers

Worth knowing

Valuation signals disagree. Cheaper than 50% of peers on free cash flow, but only 0% on earnings.
Relative to its free cash flow, Legend Biotech looks cheaper than 50% of peers; relative to its earnings, cheaper than only 0%. The valuation score blends the two, so look at which measure fits this business best.
Growing fast, still losing money. Revenue grew faster than 92% of peers, at an operating loss.
Revenue grew faster than 92% of peers, but the business runs at an operating loss (margin -13%).
Financials may be out of date. Latest financial period ended 10 months ago.
The latest financial period we have ended 10 months ago, so the scores may not reflect recent results.

StockQuotient Score

44/ 100

Oct 5 44 → Nov 4 44

Valuation

Is the price right?

8/100

Weak

3/3 inputs reported · High confidence

Since last quarter: No major changeValuation also moves with the share price every day.

Why

Weaker than most peers on:

▼ Earnings yield
▼ EBITDA yield

Compare with peers

Behind the score

Sector-normalized EBITDA, earnings, and free cash flow yields.

Earnings yield-7.1%

SEC filings (IFRS mapped) · 12 months to Dec 2025Negative (a loss or cash outflow), so it counts as zero whatever the share price30% base weight · Z-score -1.00Sector median: 0.0148 · MAD: 0.0148

EBITDA yield-1.3%

Yahoo Finance fallback · SEC enterprise value unavailable (debt or EBITDA not reported in standard form) · trailing 12 monthsNegative (a loss or cash outflow), so it counts as zero whatever the share price50% base weight · Z-score -1.00Sector median: 0.0401 · MAD: 0.0401

Free cash flow yield-3.1%

SEC filings (IFRS mapped) · 12 months to Dec 2025 · operating cash flow − capital spendingNegative (a loss or cash outflow), so it counts as zero whatever the share price20% base weight · Z-score 0.00Sector median: 0.0000 · MAD: 0.0000

Other data (not scored)

Book yield24.0%

SEC filings (IFRS mapped) · latest balance sheetReported valueInformational · 0% composite weightSector median: 0.3716 · MAD: 0.2313

Growth

Is it growing?

93/100

Strong

3/3 inputs reported · High confidence

Since last quarter: ▲ Stronger

12-month revenue up 13.2%

Why

Stronger than most peers on:

▲ 3-yr revenue
▲ Revenue growth

Compare with peers

Behind the score

Revenue and earnings-per-share growth over one year, and revenue growth over three years.

Earnings per share growthUnavailable

The loss per share widened33% base weight · Z-score -1.20Sector median: 0.0976 · MAD: 0.2991

3-year revenue growth106.4%

SEC filings (IFRS mapped) · 3 years to Dec 2025Outlier capped at sector 5th/95th percentile33% base weight · Z-score 8.59Sector median: 0.0584 · MAD: 0.0840

Revenue growth64.0%

SEC filings (IFRS mapped) · 12 months to Dec 2025Reported value33% base weight · Z-score 5.94Sector median: 0.0609 · MAD: 0.0974

Profitability

Does it earn well?

23/100

Weak

3/3 inputs reported · High confidence

Since last quarter: ▼ Weaker

Net margin fell 2.5 points to -28.8%

Why

Weaker than most peers on:

▼ ROIC
▼ ROA
▼ Operating margin

Compare with peers

Behind the score

Return on invested capital, operating margin, and return on assets.

Operating margin-13.3%

SEC filings (IFRS mapped) · 12 months to Dec 2025Reported value33% base weight · Z-score -1.67Sector median: 0.0706 · MAD: 0.1217

Return on assets-17.1%

SEC filings (IFRS mapped) · 12 months to Dec 2025Reported value33% base weight · Z-score -3.50Sector median: 0.0166 · MAD: 0.0537

Return on invested capital-25.7%

SEC filings (IFRS mapped) · 12 months to Dec 2025Reported value33% base weight · Z-score -3.03Sector median: 0.0471 · MAD: 0.1004

Other data (not scored)

Gross margin61.4%

SEC filings (IFRS mapped) · 12 months to Dec 2025Reported valueInformational · 0% composite weightSector median: 0.4697 · MAD: 0.2310

Return on equity-29.6%

SEC filings (IFRS mapped) · 12 months to Dec 2025Reported valueInformational · 0% composite weightSector median: 0.0330 · MAD: 0.1225

Risk

Debt, liquidity, price swings

Moderate

Moderate relative risk

3/3 inputs reported · High confidence

Since last quarter: No major change

Why

Helped by:

▲ Beta

Compare with peers

Behind the score

Relative to sector peers: 0 = lower relative risk · 1 = moderate · 2 = higher. Based on leverage, beta and liquidity.

Beta0.40

Yahoo Finance · 5-year monthly beta vs the marketReported value33% base weight · Z-score 0.66Sector median: 0.6250 · MAD: 0.3380

Current ratio1.96×

SEC filings (IFRS mapped) · latest balance sheetReported value33% base weight · Z-score -0.45Sector median: 2.5860 · MAD: 1.3850

Debt / equity0.32×

SEC filings (IFRS mapped) · latest balance sheetReported value33% base weight · Z-score -0.48Sector median: 0.2215 · MAD: 0.2039

Valuation, growth and profitability scores: higher is better. Risk: 0 is lower, 2 is higher. Risk is a relative proxy, not a bankruptcy probability. Scores depend on available sector peers.

Questions investors ask about Legend Biotech

Is Legend Biotech getting weaker?: Its latest SEC filing (Mar 10, 2026) got weaker in some ways: net margin fell 2.5 points to -28.8%. Its overall score is unchanged at 44/100 since Oct 28, 2026.
How is Legend Biotech valued vs its peers?: Priced higher than most peers relative to what it earns. Valuation scores 8/100 against 1,393 healthcare peers. Earnings yield -7.1% vs a peer median of 1.5% (weaker than 100% of peers).Earnings yield -7.1% vs peers 1.5% (weaker than 100% of peers).
Is Legend Biotech growing?: Yes, faster than most of its peers. Growth scores 93/100 against 1,393 healthcare peers. 3-year revenue growth 106.4% vs a peer median of 5.8% (stronger than 95% of peers).3-year revenue growth 106.4% vs peers 5.8% (stronger than 95% of peers).
How profitable is Legend Biotech?: Less profitable than most of its peers. Profitability scores 23/100 against 1,393 healthcare peers. Return on invested capital -25.7% vs a peer median of 4.7% (weaker than 81% of peers).Return on invested capital -25.7% vs peers 4.7% (weaker than 81% of peers).
How risky is Legend Biotech?: Moderate risk relative to 1,393 healthcare peers, judged on debt, liquidity and share-price swings. Beta 0.40 vs a peer median of 0.63 (stronger than 69% of peers).Beta 0.40 vs peers 0.63 (stronger than 69% of peers). A relative measure, not a bankruptcy probability.

Latest filing: what changed

Quarter ended Dec 31, 2025 · filed Mar 10, 2026 · compared with the quarter ended Sep 30, 2025

Got weaker

Net margin fell 2.5 points to -28.8%

	Previous quarter	Latest quarter	Change
Revenue (12 months)	909.0M USD	1.0B USD	+13.2%
Net income (12 months)	−239.7M USD	−296.8M USD	+23.8%
Free cash flow (12 months)	−188.7M USD	−128.8M USD	−31.7%
Debt	314.8M USD	319.1M USD	+1.4%
Cash	278.9M USD	901.9M USD	+223.4%

From the company’s own SEC filings, as filed. Twelve-month figures roll forward one quarter at a time.

Industry valuation context

Industry: Biotechnology · 132 companies

Valuations in Biotechnology are within their usual range since 2016.

48% of months since 2016 were valued lower than now.
22% of companies are in the most expensive fifth of their own price-to-sales history.
Median price-to-sales is +530% vs the whole market, against a usual +637%.

2016Shaded: most expensive fifth of its range2026

Earnings-based measures are left out for now because many companies in Biotechnology are losing money.

Financials

Fiscal years from SEC annual filings · change vs the prior year

Key ratios	FY 2021	FY 2022	FY 2023	FY 2024	FY 2025	Change
Gross margin	100.0%	44.1%	49.4%	65.5%	61.4%	▼ 4.1 pts
Operating margin	—	—	-185.2%	-49.3%	-13.3%	▲ 36 pts
Net margin	-586.4%	-381.5%	-181.8%	-28.2%	-28.8%	▼ 0.6 pts
Return on assets (ROA)	-36.1%	-33.5%	-28.0%	-10.6%	-17.1%	▼ 6.5 pts
Return on equity (ROE)	-52.7%	-60.0%	-41.4%	-17.0%	-29.6%	▼ 13 pts
Free cash flow margin	-349.7%	-189.9%	-145.0%	-25.2%	-12.5%	▲ 13 pts
Current ratio	4.14×	3.69×	6.92×	4.62×	1.96×	▼ 58%
Quick ratio	4.14×	3.66×	6.83×	4.54×	1.91×	▼ 58%
Debt to equity	0.16×	0.35×	0.22×	0.29×	0.32×	▲ 10%
Interest coverage	—	—	-24.22×	-14.33×	-6.38×	▲ 55%

LEGN price history

Price history is added with the daily price update and will appear after the next one.

Similar companies

Sector leaderboards

BB Biotech AGBBZA.DE100/ 100

Arbutus Biopharma CorporationABUS97/ 100

Q32 Bio Inc.QTTB97/ 100

Bringing the fundamentals into focus…

Overall health

Strength: growing faster than most peersgrowing faster than peers

Drawback: less profitable than most peersless profitable than peers

Drawback: its shares are priced higher than most peers relative to what it earnspriced higher than peers for its earnings

About average: risk (debt, liquidity and share-price swings)risk

Ranks #753 of 1,157 healthcare companies (bottom 36%)

See how it ranks against its peers

Worth knowing

Valuation signals disagree. Cheaper than 50% of peers on free cash flow, but only 0% on earnings.

Relative to its free cash flow, Legend Biotech looks cheaper than 50% of peers; relative to its earnings, cheaper than only 0%. The valuation score blends the two, so look at which measure fits this business best.

Growing fast, still losing money. Revenue grew faster than 92% of peers, at an operating loss.

Revenue grew faster than 92% of peers, but the business runs at an operating loss (margin -13%).

Financials may be out of date. Latest financial period ended 10 months ago.

The latest financial period we have ended 10 months ago, so the scores may not reflect recent results.

Questions investors ask about Legend Biotech

Is Legend Biotech getting weaker?

Its latest SEC filing (Mar 10, 2026) got weaker in some ways: net margin fell 2.5 points to -28.8%. Its overall score is unchanged at 44/100 since Oct 28, 2026.

How is Legend Biotech valued vs its peers?

Priced higher than most peers relative to what it earns. Valuation scores 8/100 against 1,393 healthcare peers. Earnings yield -7.1% vs a peer median of 1.5% (weaker than 100% of peers).Earnings yield -7.1% vs peers 1.5% (weaker than 100% of peers).

Is Legend Biotech growing?

Yes, faster than most of its peers. Growth scores 93/100 against 1,393 healthcare peers. 3-year revenue growth 106.4% vs a peer median of 5.8% (stronger than 95% of peers).3-year revenue growth 106.4% vs peers 5.8% (stronger than 95% of peers).

How profitable is Legend Biotech?

Less profitable than most of its peers. Profitability scores 23/100 against 1,393 healthcare peers. Return on invested capital -25.7% vs a peer median of 4.7% (weaker than 81% of peers).Return on invested capital -25.7% vs peers 4.7% (weaker than 81% of peers).

How risky is Legend Biotech?

Moderate risk relative to 1,393 healthcare peers, judged on debt, liquidity and share-price swings. Beta 0.40 vs a peer median of 0.63 (stronger than 69% of peers).Beta 0.40 vs peers 0.63 (stronger than 69% of peers). A relative measure, not a bankruptcy probability.

Previous quarter

Latest quarter

Change

Revenue (12 months)

909.0M USD

1.0B USD

+13.2%

Net income (12 months)

−239.7M USD

−296.8M USD

+23.8%

Free cash flow (12 months)

−188.7M USD

−128.8M USD

−31.7%

Debt

314.8M USD

319.1M USD

+1.4%

Cash

278.9M USD

901.9M USD

+223.4%

Key ratios

FY 2021

FY 2022

FY 2023

FY 2024

FY 2025

Change

Gross margin

100.0%

44.1%

49.4%

65.5%

61.4%

▼ 4.1 pts

Operating margin

—

-185.2%

-49.3%

-13.3%

▲ 36 pts

Net margin

-586.4%

-381.5%

-181.8%

-28.2%

-28.8%

▼ 0.6 pts

Return on assets (ROA)

-36.1%

-33.5%

-28.0%

-10.6%

-17.1%

▼ 6.5 pts

Return on equity (ROE)

-52.7%

-60.0%

-41.4%

-17.0%

-29.6%

▼ 13 pts

Free cash flow margin

-349.7%

-189.9%

-145.0%

-25.2%

-12.5%

▲ 13 pts

Current ratio

4.14×

3.69×

6.92×

4.62×

1.96×

▼ 58%

Quick ratio

4.14×

3.66×

6.83×

4.54×

1.91×

▼ 58%

Debt to equity

0.16×

0.35×

0.22×

0.29×

0.32×

▲ 10%

Interest coverage

—

-24.22×

-14.33×

-6.38×

▲ 55%